MPS Pharmaa Ltd
Incorporated in 1997, MPS Pharmaa Ltd manufactures and sells pharmaceutical
products[1]
- Market Cap ₹ 3.63 Cr.
- Current Price ₹ 1.90
- High / Low ₹ 2.47 / 1.57
- Stock P/E
- Book Value ₹ 0.04
- Dividend Yield 0.00 %
- ROCE -13.1 %
- ROE -177 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 51.9 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 35.9%
- Company has a low return on equity of -61.4% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.95 | |
| Operating Profit | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.95 |
| OPM % | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||||
| 0.00 | 0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 | |
| Interest | 1.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.15 |
| Profit before tax | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -1.06 |
| Tax % | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | -3.77% |
| -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -1.02 | |
| EPS in Rs | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.53 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 12% |
| 3 Years: | 1% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | 11% |
| 3 Years: | -8% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | -30% |
| 5 Years: | -34% |
| 3 Years: | -61% |
| Last Year: | -177% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -19.04 |
| 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.52 | |
| 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 | 0.89 | |
| Total Liabilities | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.48 |
| 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.66 | |
| CWIP | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 | 2.41 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 1.87 | |
| Total Assets | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.48 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.16 | 1.25 | 0.37 | -0.34 | 0.61 | -0.49 | -0.93 | -4.34 | -0.87 | -0.63 | -0.57 | -0.59 | |
| -0.44 | -0.05 | 0.63 | 0.30 | -0.22 | 0.46 | 1.54 | 0.46 | -0.10 | 0.12 | 0.38 | 0.52 | |
| -1.75 | -1.19 | -0.98 | 0.00 | -0.39 | 0.03 | -0.61 | 3.88 | 0.96 | 0.51 | 0.18 | 0.07 | |
| Net Cash Flow | -0.03 | 0.01 | 0.02 | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 1.72 | 1.20 | 1.00 | -0.04 | 0.39 | -0.04 | 0.22 | -3.88 | -0.97 | -0.51 | -0.19 | -0.07 |
| CFO/OP | 267% | -292% | -5% | 64% | -84% | 73% | 22% | 638% | 92% | 79% | 74% | 62% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | ||||||
| Inventory Days | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | |||||
| Days Payable | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | |||||
| Cash Conversion Cycle | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | ||||||
| Working Capital Days | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | ||||||
| ROCE % | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% | -13.14% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Market Capitalization Rs in Lacs |
|
||||||
| Number of Employees on Rolls employees |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.
-
PFA Statement Of Investor Complaints For The Quarter Ended 30Th June, 2026
11 Jul - Investor complaints statement for quarter ended 30 June 2026 shows nil complaints throughout.
-
Closure of Trading Window
27 Jun - Trading window closes from 1 July 2026 until 48 hours after Q1 FY2026-27 results.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Submitted Annual Secretarial Compliance Report for year ended 31 March 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - PFA Newspaper Publication w.r.t Audited Financial Results for the Quarter and Year ended 31st March, 2026
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
a) MPSPL (Formerly Advik Laboratories
Ltd) is in the business of manufacturing, marketing, trading, and export of Pharma Products.
b) The company has its manufacturing facility at Sohna.
c) It has various independent contract
/third-party manufacturers based across
the country